Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus - Trial NCT06419816
Access comprehensive clinical trial information for NCT06419816 through Pure Global AI's free database. This phase not specified trial is sponsored by Daewoong Pharmaceutical Co. LTD. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 480 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Daewoong Pharmaceutical Co. LTD.
Timeline & Enrollment
N/A
Jun 30, 2024
Jun 30, 2026
Primary Outcome
change in glycated hemoglobin (HbA1c) levels
Summary
This clinical study aims to evaluate the effects of using the WellCheck mobile application
 on blood glucose, blood pressure, and weight among Type 2 diabetes patients in real primary
 care settings. It is a prospective, multi-center, cluster-randomized, pragmatic clinical
 trial. Patients who can use the digital healthcare mobile application without difficulty are
 recruited based on the clinical judgment of the attending physician.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419816
Non-Device Trial